ER-100: First Human Trial of Partial Epigenetic Reprogramming (OSK)

Abstract

On January 28, 2026, the FDA cleared the first-ever human trial of a partial epigenetic reprogramming therapy. On June 9, 2026, Life Biosciences dosed the first patient with ER-100 — an AAV2 gene therapy delivering three Yamanaka factors OCT4, SOX2, KLF4 (OSK) to retinal ganglion cells under doxycycline control. This modular Data Unit documents what ER-100 is, how the trial is designed, and why it validates a prediction made in Denigma's own article From Ageing to Rejuvenation (2013): "Manipulation of only one defined gene can make old organisms young again... I know it is possible to re-awake it also in our body cells!"

Human eye in profile receiving AAV2 gene therapy with three glowing OSK factors rejuvenating aged optic nerve fibers from cracked to golden healthy

Why This Matters for Denigma

Denigma was built on the concept of a Data Unit as the quark of knowledge and an ontology bridging semantic gaps. The 2013 article From Ageing to Rejuvenation stated:

There is a real rejuvenation process, sleeping in our genome. It is activated as we pass our cells to the next generation. Therefore our children, regardless of which age we get them, have a restored lifespan. Ageing was truly reset.

ER-100 is the first clinical attempt to re-awake that process in situ, without removing cells from the body.

What is ER-100?

ER-100 is an investigational adeno-associated virus serotype 2 (AAV2) gene therapy designed to produce controlled expression of OCT4, SOX2 and KLF4 — collectively referred to as OSK — in retinal cells.

Vector: AAV2, well-proven for retinal delivery via single intravitreal injection
Payload: OSK (without c-MYC to reduce tumorigenic risk). Engineered with doxycycline-responsive promoter (Tet-On)
Activation: Daily oral doxycycline for 56 days (8 weeks) to induce OSK expression. Oral prednisolone taper to minimize AAV2 immune inflammation
Safety switch: Expression stops when doxycycline is withdrawn
Target cells: Retinal ganglion cells (RGCs), which do not divide and are affected in age-related optic neuropathies

Full reprogramming with OSKM (OCT4, SOX2, KLF4, c-MYC) creates induced pluripotent stem cells but erases cell identity and risks teratoma. Partial reprogramming with OSK transiently resets epigenetic age while maintaining cell identity.

Trial Design: NCT07290244

Identifier: NCT07290244 — First-in-human, Phase 1, open-label, single-dose, safety and tolerability
Sponsor: Life Biosciences, Boston (company co-founded by David Sinclair, Harvard/Glenn Center)
FDA IND clearance: January 28, 2026
First patient dosed: June 9, 2026
Population: 18 adults aged 40-85 with optic neuropathies
Dose escalation: 12 with open-angle glaucoma (OAG)
Expansion: 6 with non-arteritic anterior ischemic optic neuropathy (NAION) — often called "stroke of the eye"
Dose Level 1: 2x10^11 vg (vector genomes) single intravitreal administration
Sites: 4 US sites, sentinel dosing with 28-day DSMB review per level
Follow-up: 5 years with viral shedding and anti-AAV2 antibody monitoring
Primary completion: May 2027

Interim Data (October 2026)

Life Biosciences reported interim Phase 1 data for three participants with OAG at Dose Level 1:

A single intravitreal administration combined with daily oral doxycycline was well tolerated through Day 56, according to the company. No serious adverse events.

Visual field preliminary improvements were mentioned in company updates, but safety endpoints only — no efficacy claim yet. This is not approval to market and not proof of human aging reversal.

Preclinical Foundation

2006: Shinya Yamanaka Nobel Prize discovery — four factors can reprogram somatic cells to pluripotency
2020: Lu et al., Nature (Sinclair lab) — OSK delivered by AAV2 restored youthful epigenetic information and vision in aged and glaucomatous mice via TET-dependent demethylation
2023-2025: Multiple labs showed transient OSK extends lifespan/healthspan in progeroid and naturally aged mice without teratoma when c-MYC omitted and duration limited
2026 Bonn parallel: Direct conversion of blood precursors from 80-year-old donor into neural stem cells with molecular age <20 years (Aging Cell) provides orthogonal evidence for epigenetic de-aging

What ER-100 Does NOT Prove (Yet)

No human evidence that ER-100 reverses biological age, extends lifespan, or treats dementia
In vivo reprogramming rejuvenated cells in lab and mouse retina, not whole organism
5-year follow-up required due to AAV persistence and theoretical risks
Trial tests optic nerve, not systemic aging

Implications for Denigma's Ontology

ER-100 provides a concrete intervention linking:

Gene → Epigenetic Clock → Tissue Function
Aging as information loss (Information Theory of Aging) → Information restoration via OSK
Data Unit → Knowledge Graph triple → Agentic hypothesis testing (as in EvoAge)

It also creates a bridge to your Transposable Elements post: OSK reprogramming transiently suppresses LINE-1 retrotransposon activation, which otherwise triggers cGAS-STING and inflammaging.

Next Steps for Denigma

Monitor NCT07290244 readouts (safety, RNFL thickness, visual field, epigenetic clock in RGCs if biopsied)
Add ER-100 as intervention node in aging knowledge graph with relations to OCT4, SOX2, KLF4, AAV2, glaucoma, NAION
Link to dietary restriction and GLP-1 gerotherapeutics (same DunedinPACE endpoint)
Update From Ageing to Rejuvenation article with 2026 human data

References

Life Biosciences press release Jan 28 2026: FDA Clearance of IND Application for ER-100 in Optic Neuropathies
Life Biosciences press release Jun 9 2026: First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies (NCT07290244)
ClinicalTrials.gov NCT07290244 — Evaluating ER-100 for Safety in People With Glaucoma or NAION
Lu et al. 2020 Nature — Reprogramming to recover youthful epigenetic information and restore vision
Bonn Aging Cell Oct 2026 — Protracted fate acquisition and epigenetic de-aging during induced neural stem cell conversion of human blood (80-year-old → <20-year molecular age)
FightAging.org Oct 2026 — Life Biosciences Reports Initial Results from the First Reprogramming Trial
RegulatoryImpact 2026 — ER-100 Enters the Clinic: What FDA Will Need to See